“We expect to make major announcements regarding Zalemark, as well as Hypertension Diagnostics, Inc. (OTC: HDII) in the very near future. We have been in advanced discussions with some impressive private companies that are seeking our assistance in achieving public listings in the United States through these vehicles.”
Mr. Xu met PM Trudeau and noted; “I was so inspired to meet and receive positive encouragement from our Prime Minister.”
This guy is bringing in a huge company to merge with HDII. Look what he did with ZMRK last week.
One very real possibility is SD Gerpang Biotec. “The company has 220 employees and more than 10 international and national patents. The annual turnover is nearly one billion yuan.” This is $145 million in revenue a year.
MAY 21, 2019 BY ZMRK Mr. Robert Xu, the current CEO of Zalemark Holdings Co. Inc. is visiting SD Gerpang Biotec Co. Ltd, Shangdong China now Mr. Robert Xu meets Mr. Frank Lu , the Chairman of SD Gerpang Biotec Co. Ltd. and his team, according to a tight schedule. They have a few great meetings in Yiantian, Jinan offices and the private clubs . http://zalemark.com/?p=397
SD Gerpang Biotec: Gengbang Medical Group is an innovative technology-based private enterprise located in the Pharmaceutical Valley Industrial Park of Jinan High-tech Zone. The main business scope of the group includes biomedical research and development, medical information software development and sales, medical high-tech introduction, medical high-quality consumables production. And sales, health care products, pharmaceuticals, medical equipment supplies agents and sales. The company has 220 employees and more than 10 international and national patents. The annual turnover is nearly one billion yuan.
Since its establishment in 2006 , the Group's marketing team has had an 11-year marketing history with annual sales exceeding RMB 300 million. The marketing team specializes in promoting pharmaceutical medical devices and consumables. Representative products: Xintailin, Dangli Ganning Capsule, ganglioside, surgical orthopedic consumables and other products. More than 50 in-service marketing staff , more than 2,000 agents . The marketing department, the commerce department, the training department, and the customer service department are fully equipped and fully functional. The business scope covers more than 20 provinces across the country : Beijing, Shanghai, Zhejiang, Jiangsu, Shandong, Hebei, Henan, Anhui, Hunan, Hubei, Sichuan, Chongqing, Guangdong, Fujian, Liaoning, Heilongjiang, etc., and has more than 1,000 Home hospitals cooperate.
In the past five years, the Group has established strategic partnerships with a number of universities in biomedicine in Toronto, Montreal, Boston, New York and Connecticut, and has established extensive government resource management and business contacts. Relationships have now resulted in multiple levels of investment for more than 20 projects. In Toronto, Montreal and New York, it has invested more than 50 million yuan to screen the world's first-class projects in the biomedical industry.
The four major international projects that have been introduced:
Gene-coated cardiac stent from McGill University, Canada, hepatitis B virus cure vaccine from Yale University, male infertility detection technology at Mount Sinai Hospital, Canada, and the American Maiwei Stroke Clearing Project. The global production bases of the four major projects will be located in the Jinan High-tech Zone. After the project is matured, it will be built in Jinan Pharmaceutical Valley and Life Science City for 5-7 years to build a world-class biomedical industrial park. The park plans to acquire 500 mu of land and gradually establish five multi-functional parks: biomedical incubator and medium Test Base Park; Pharmaceutical Logistics and Pharmaceutical Products Trade Complex; Innovative Medicine and Medical Devices, Consumables and Health Products Industrial Park; International Cardiovascular and Rehabilitation Park; Established Talent Training Base with University of Toronto, Tsinghua University and Shandong University - Pharmaceutical Business School Campus.
In October 2015, the first “ China - Canada Biomedical New Technology Cooperation Forum ” was held in Jinan, Shandong Province with Harvard University, Massachusetts Institute of Technology, Yale University, University of Michigan, McGill University, University of Toronto, McMahon. The University of Queens, Queen's University, Bethune Medical Development Association and other units have jointly established the " China - North America Innovation Medical Investment and Industry Alliance " , which brings the world's most advanced biomedical technology to China and promotes the national pharmaceutical industry with technological innovation. development of. The forum is held once a year.
In the next five years of development, the group company will be based in Shandong, focus on North America, cooperate in research and development of new technologies from the innovation of the pharmaceutical industry chain, introduce a number of world-class projects, and establish a nationwide Greater China marketing management platform in the distribution agency market. In the hospital terminal market, establish a platform for the professional chain hospital with reasonable technology and reasonable operation.
Market Data 
Markets 
AI
